Hjem › Kronisk lymfatisk leukæmi › South Carolina
Kronisk lymfatisk leukæmi kliniske forsøg i South Carolina
5 studier for Kronisk lymfatisk leukæmi søger deltagere på steder i South Carolina.
Byer i South Carolina
Officiel studietekst (engelsk)
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- AnMed Health Cancer Center, Anderson
- Prisma Health Richland Hospital, Columbia
- McLeod Regional Medical Center, Florence
- og 12 flere
RekruttererObservationsstudieFrivillige med god helbredstilstand velkomne
Alder 40 til 75 · Alle køn · Opdateret 2. okt. 2026 · NCT05334069Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Prisma Health Cancer Institute - Spartanburg, Boiling Springs
- Ralph H Johnson VA Medical Center, Charleston
- Medical University of South Carolina, Charleston
- og 6 flere
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 30. sep. 2026 · NCT04269902A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Medical University of South Carolina, Charleston
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT06973187Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- Bon Secours St. Francis Cancer Center, Greenville
RekruttererFase 1/2
Alder 12 og opefter · Alle køn · Opdateret 3. sep. 2026 · NCT04588922Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL
- Hollings Cancer Center at Medical University of South Carolina, Charleston
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 27. mar. 2026 · NCT05702853Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.